Silver Book Fact

Reducing risk of fracture from 8% to 2% reduces the 5-year fracture incidence from approximately 34% to 10%.

Lindsay R, Pack S, Li Z. Longitudinal Progression of Fracture Prevalence through a Population of Postmenopausal Women with Osteoporosis. Osteoporos Int. 2005; 16(3): 306-12. http://www.ncbi.nlm.nih.gov/pubmed/15455193

Reference

Title
Longitudinal Progression of Fracture Prevalence through a Population of Postmenopausal Women with Osteoporosis
Publication
Osteoporos Int
Publication Date
2005
Authors
Lindsay R, Pack S, Li Z
Volume & Issue
Volume 16, Issue 3
Pages
306-12
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Reducing risk of fracture from 8% to 2% reduces the 5-year fracture incidence from approximately 34% to 10%.  
  • Alendronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by as much as 8% over 3-years in postmenopausal women with osteoporosis.  
  • Raloxifene, a selective estrogen receptor modulator (SERM) has been shown to increase vertebral bone mineral density (BMD) by 2% to 3% after 3 years.  
  • Teriparatide, or human recombinant PTH, has been shown to decrease vertebral fractures by 65% to 69%, and non-vertebral fragility fractures by around 53%.  
  • Researchers are looking at the use of micro-computed tomography and magnetic resonance imaging to better understand the relationship between bone structure and fracture risk. Other tools are being evaluated for…